Dr. Alumkal graduated summa cum laude from the University of Texas with a B.A. in Biology. Then, he received his medical degree from Baylor College of Medicine. He completed an internship, residency, and chief residency at UT Southwestern Medical Center. After completing a clinical fellowship in medical oncology at Johns Hopkins University, Dr. Alumkal completed a post-doctoral fellowship focused on cancer epigenetics in the Jim Herman Laboratory at Johns Hopkins. Dr. Alumkal joined the Knight Cancer Institute Prostate Cancer Research Program at Oregon Health and Science University (OHSU) in 2007 and became the co-Leader of the Program in 2013. In 2014, Dr. Alumkal was honored with the Richard T. Jones New Investigator Award for exceptional promise early in a career in biomedical research in Oregon. He was also named the inaugural holder of the Wayne D. Kuni and Joan E. Kuni Endowed Chair for Prostate Cancer Research at OHSU in 2017.

In 2019, Dr. Alumkal re-located to the University of Michigan to lead the Genitourinary Medical Oncology Section in the Division of Hematology-
Oncology and the Rogel Cancer Center, where he is a Professor of Internal Medicine. He was named a Rogel Cancer Center Rogel Scholar in 2019 and was elected to the American Society for Clinical Investigation that same year. Since 2020, he has been a Co-Leader of the Translational and Clinical Research Program in the Rogel Cancer Center. In 2021, Dr. Alumkal was named the inaugural Wicha Family Professor of Oncology at the University of Michigan.

The Alumkal Laboratory’s main emphasis is to understand how tumors change and adapt in response to treatment. The most important goals of Dr. Alumkal’s studies are to identify therapies that effectively target and interdict lethal prostate cancer progression in the laboratory and to conduct innovative clinical trials designed to validate the molecular and clinical effectiveness of novel therapeutic agents.